Adelmidrol: A New Promising Antioxidant and Anti-Inflammatory Therapeutic Tool in Pulmonary Fibrosis
Adelmidrol: A New Promising Antioxidant and Anti-Inflammatory Therapeutic Tool in Pulmonary Fibrosis
复制标题
DOI：
10.3390/antiox9070601
复制
发表时间：
2020-07-01
期刊：
影响因子：
7
通讯作者：
Di Paola, Rosanna
中科院分区：
文献类型：
--
作者：
Fusco, Roberta;Cordaro, Marika;Di Paola, Rosanna
背景资料：慢性肺疾病的特征在于由于复杂的多细胞反应和自由氧自由基的产生而导致的气道重塑。它们导致肺功能的进行性下降。阿替米德罗是棕榈酰乙醇胺（PEA）的类似物，后者是一种众所周知的抗炎和抗氧化化合物。在这项研究中，我们研究了艾咪洛尔（10 mg/Kg）对博莱霉素诱导的小鼠肺纤维化的疗效。研究方法：在第一天进行博来霉素鼻内给药，并且在接下来的21天，用艾咪醇（10 mg/Kg）处理小鼠。结果：每天记录存活率和体重增加。在实验结束时，给予阿地米洛尔的动物显示炎性细胞的气道浸润、髓过氧化物酶（MPO）活性和促炎性细胞因子过表达（IL、6 IL-1 β、TNF-α和TGF-1 β）减少。此外，阿德米罗治疗能够管理抗氧化剂的显著丧失和氧化剂负荷的升高，如MDA、SOD和GSH水平所示，并减少一氧化氮的产生。它还能够显著调节JAK 2/STAT 3和I κ B α/NF-κ B通路。肺组织的组织学检查显示样品损伤、肥大细胞脱颗粒、糜酶活性和胶原沉积减少。结论：总之，我们的研究结果表明，作为一种治疗方法，在肺纤维化的治疗。
Background: Chronic pulmonary diseases are characterized by airway remodeling due to complex multicellular responses and the production of free oxygen radicals. They lead to a progressive decline of pulmonary functions. Adelmidrol is an analogue of palmitoylethanolamide (PEA), which is a well-known anti-inflammatory and anti-oxidant compound. In this study, we investigated the efficacy of adelmidrol (10 mg/Kg) for bleomycin-induced pulmonary fibrosis in mice. Methods: Bleomycin intratracheal administration was performed on the first day and for the following twenty-one days, mice were treated with adelmidrol (10 mg/Kg). Results: The survival rate and body weight gain were recorded daily. At the end of the experiment, adelmidrol-administered animals showed reduced airway infiltration by inflammatory cells, Myeloperoxidase (MPO) activity, and pro-inflammatory cytokine overexpression (IL,6 IL-1 beta, TNF-alpha, and TGF-1 beta). Moreover, adelmidrol treatment was able to manage the significant incapacity of antioxidants and elevation of the oxidant burden, as shown by the MDA, SOD, and GSH levels and decreased nitric oxide production. It was also able to significantly modulate the JAK2/STAT3 and I kappa B alpha/NF-kB pathway. Histologic examination of the lung tissues showed reduced sample injury, mast cell degranulation, chymase activity, and collagen deposition. Conclusions: In sum, our results propose adelmidrol as a therapeutic approach in the treatment of pulmonary fibrosis.